APOE ε4 and risk for Alzheimer's disease: Do regionally distributed white matter hyperintensities play a role?

[1]  Wiro J. Niessen,et al.  The Rotterdam Scan Study , 2015 .

[2]  R. Mayeux,et al.  Genetics of Alzheimer’s Disease in Caribbean Hispanic and African American Populations , 2014, Biological Psychiatry.

[3]  R. Mayeux,et al.  Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease , 2013, Nature Neuroscience.

[4]  Owen T. Carmichael,et al.  White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment , 2013, Alzheimer's & Dementia.

[5]  Nora Mattek,et al.  Neuropathologic basis of white matter hyperintensity accumulation with advanced age , 2013, Neurology.

[6]  K. Lunetta,et al.  APOE genotype and MRI markers of cerebrovascular disease , 2013, Neurology.

[7]  Jordan Muraskin,et al.  White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? , 2013, JAMA neurology.

[8]  A. Brickman,et al.  Spatial Distribution of Cerebral White Matter Lesions Predicts Progression to Mild Cognitive Impairment and Dementia , 2013, PloS one.

[9]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[10]  W. M. van der Flier,et al.  Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia , 2013, Neurology.

[11]  W. Jagust,et al.  Apolipoprotein E, Not Fibrillar β-Amyloid, Reduces Cerebral Glucose Metabolism in Normal Aging , 2012, The Journal of Neuroscience.

[12]  A. Brickman,et al.  Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. , 2012, Archives of neurology.

[13]  A. Brickman,et al.  Metabolic syndrome and localization of white matter hyperintensities in the elderly population , 2012, Alzheimer's & Dementia.

[14]  V. Gudnason,et al.  Brain tissue volumes by APOE genotype and leisure activity—the AGES-Reykjavik Study , 2012, Neurobiology of Aging.

[15]  Naftali Raz,et al.  Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. , 2012, Biochimica et biophysica acta.

[16]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[17]  Menno P. Witter,et al.  A pathophysiological framework of hippocampal dysfunction in ageing and disease , 2011, Nature Reviews Neuroscience.

[18]  Jordan Muraskin,et al.  Quantitative approaches for assessment of white matter hyperintensities in elderly populations , 2011, Psychiatry Research: Neuroimaging.

[19]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[20]  C. DeCarli,et al.  Subclinical cerebrovascular disease in mild cognitive impairment , 2009, Neurology.

[21]  Jordan Muraskin,et al.  Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter? , 2009, Dialogues in clinical neuroscience.

[22]  Yaakov Stern,et al.  Reduction in cerebral blood flow in areas appearing as white matter hyperintensities on magnetic resonance imaging , 2009, Psychiatry Research: Neuroimaging.

[23]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[24]  Yaakov Stern,et al.  Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. , 2008, Archives of neurology.

[25]  A. Brickman,et al.  Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. , 2008, Archives of neurology.

[26]  T. Berzin,et al.  Microvascular injury and blood–brain barrier leakage in Alzheimer's disease , 2007, Neurobiology of Aging.

[27]  D. Harvey,et al.  Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD , 2006, Neurology.

[28]  L S Honig,et al.  Aggregation of vascular risk factors and risk of incident Alzheimer disease , 2005, Neurology.

[29]  D. Holtzman,et al.  Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model , 2005, The Journal of Neuroscience.

[30]  K. Ishii,et al.  Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  P. Gorelick,et al.  Risk Factors for Vascular Dementia and Alzheimer Disease , 2004, Stroke.

[32]  Tomio Inoue,et al.  Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Jan Cees de Groot,et al.  Interaction Between Hypertension, apoE, and Cerebral White Matter Lesions , 2004, Stroke.

[34]  J. Boulenger,et al.  Prevalence of DSM ^ IV psychiatric disorder in the French elderly population , 2022 .

[35]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[36]  William J Jagust,et al.  Brain function and cognition in a community sample of elderly Latinos , 2002, Neurology.

[37]  M H Buonocore,et al.  Brain structure and cognition in a community sample of elderly Latinos , 2002, Neurology.

[38]  R. Costa,et al.  Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan , 2001, Neurology.

[39]  A Hofman,et al.  Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study , 2001, Journal of neurology, neurosurgery, and psychiatry.

[40]  J M Wardlaw,et al.  Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study: the Rotterdam Scan Study , 2001, Journal of neurology, neurosurgery, and psychiatry.

[41]  E. Mori,et al.  Effect of the Apolipoprotein E ε4 Allele on White Matter Hyperintensities in Dementia , 2000 .

[42]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Mori,et al.  Effect of the apolipoprotein E epsilon4 allele on white matter hyperintensities in dementia. , 2000, Stroke.

[44]  C. Rorden,et al.  Stereotaxic display of brain lesions. , 2000, Behavioural neurology.

[45]  P. Scheltens,et al.  Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias , 1999 .

[46]  L. Wahlund,et al.  White Matter Lesions in Alzheimer Patients Are Influenced by Apolipoprotein E Genotype , 1999, Dementia and Geriatric Cognitive Disorders.

[47]  P. Scheltens,et al.  Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. , 1999, Archives of neurology.

[48]  G. Wilcock,et al.  Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population , 1998, International journal of geriatric psychiatry.

[49]  K. Marder,et al.  The APOE- (cid:101) 4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics , 2001 .

[50]  G. Ratcliff,et al.  Sex differences in brain aging: a quantitative magnetic resonance imaging study. , 1998, Archives of neurology.

[51]  K. Blennow,et al.  A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality , 1998, Journal of neurology, neurosurgery, and psychiatry.

[52]  C. Broeckhoven,et al.  Dutch hereditary cerebral amyloid angiopathy: Structural lesions and apolipoprotein E genotype , 1997, Annals of neurology.

[53]  H. Braak,et al.  Evolution of the neuropathology of Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.

[54]  C. Wernstedt,et al.  Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain , 1995, Neuron.

[55]  B. Tycko,et al.  Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease , 1995, Neurology.

[56]  S. Gauthier,et al.  Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies , 1994, Annals of neurology.

[57]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[58]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[59]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[60]  H. Vinters,et al.  Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage. , 1983, Stroke.

[61]  H. Vinters,et al.  Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. , 1983, Stroke.